Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review
Turkish Journal of Gastroenterology, vol.36, no.6, pp.336-342, 2025 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Review
- Volume: 36 Issue: 6
- Publication Date: 2025
- Doi Number: 10.5152/tjg.2025.25148
- Journal Name: Turkish Journal of Gastroenterology
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Page Numbers: pp.336-342
- Keywords: Etrasimod, treatment, ulcerative colitis
- Akdeniz University Affiliated: No
Abstract
Ulcerative colitis (UC) is a chronic, inflammatory disease of the colon. The unpredictable, systemic, and debilitating nature of UC puts disease management and patient monitoring at a pivotal point. Despite substantial development in pharmacotherapies for UC in recent years, a significant proportion of patients either fail to respond to treatment or lose their response over the course of the disease. The backbone of disease management in UC is 5-aminosalicylic acid (5-ASA), but patients unresponsive to 5-ASA or with severe disease require advanced therapies including tumor necrosis factor-alpha inhibitors (TNFi), anti-integrins, anti-interleukins and small molecule therapy, Janus kinase (JAK) inhibitors, and S1PR modulators. This review will briefly overview the current state of medical therapeutic options in UC, with further detailing the molecular and clinical aspects of Etrasimod, a sphingosine-1-phosphate receptor (S1PR) modulator.